Switch theme
Sign up to access all valuation multiples
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company’s current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
18
Last FY Revenue $9.8M
Last FY EBITDA -$7.0M
$37.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, IRLAB Therapeutics achieved revenue of $9.8M and an EBITDA of -$7.0M.
IRLAB Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IRLAB Therapeutics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $9.8M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$7.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -72% | XXX | XXX | XXX |
| EBIT | XXX | -$7.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | -81% | XXX | XXX | XXX |
| Net Profit | XXX | -$8.6M | XXX | XXX | XXX |
| Net Margin | XXX | -88% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, IRLAB Therapeutics's stock price is SEK 7 (or $1).
IRLAB Therapeutics has current market cap of SEK 382M (or $39.4M), and EV of SEK 360M (or $37.1M).
See IRLAB Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $37.1M | $39.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, IRLAB Therapeutics has market cap of $39.4M and EV of $37.1M.
IRLAB Therapeutics's trades at 3.8x EV/Revenue multiple, and -5.3x EV/EBITDA.
Equity research analysts estimate IRLAB Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IRLAB Therapeutics's P/E ratio is not available.
See valuation multiples for IRLAB Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $39.4M | XXX | $39.4M | XXX | XXX | XXX |
| EV (current) | $37.1M | XXX | $37.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -5.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -4.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -4.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIRLAB Therapeutics's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.0M for the same period.
IRLAB Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IRLAB Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for IRLAB Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -72% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 181% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IRLAB Therapeutics acquired XXX companies to date.
Last acquisition by IRLAB Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . IRLAB Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is IRLAB Therapeutics headquartered? | IRLAB Therapeutics is headquartered in Sweden. |
| How many employees does IRLAB Therapeutics have? | As of today, IRLAB Therapeutics has 18 employees. |
| Who is the CEO of IRLAB Therapeutics? | IRLAB Therapeutics's CEO is Mr. Gunnar Olsson. |
| Is IRLAB Therapeutics publicy listed? | Yes, IRLAB Therapeutics is a public company listed on STO. |
| What is the stock symbol of IRLAB Therapeutics? | IRLAB Therapeutics trades under IRLAB A ticker. |
| When did IRLAB Therapeutics go public? | IRLAB Therapeutics went public in 2017. |
| Who are competitors of IRLAB Therapeutics? | Similar companies to IRLAB Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of IRLAB Therapeutics? | IRLAB Therapeutics's current market cap is $39.4M |
| Is IRLAB Therapeutics profitable? | Yes, IRLAB Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
